SCHEMBL7079430

SCHEMBL7079430

CCN(CC)CCOC(C)Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 3/20 0.37
TSHR P16473 1/20 0.37
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
LMNA P02545 1/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
EBP Q15125 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14920988 0.82 MEN1 (0.41) MEN1POLBKMT2AKDM4ETSHR
SCHEMBL5002480 0.82 MEN1 (0.41) MEN1POLBKMT2AKDM4ETSHR
SCHEMBL23791204 0.78 MEN1 (0.39) MEN1POLBKMT2AKDM4ETSHR
SCHEMBL749808 0.78 MEN1 (0.39) MEN1POLBKMT2AKDM4ETSHR
SCHEMBL25492652 0.78 MEN1 (0.39) MEN1POLBKMT2AKDM4ETSHR
SCHEMBL12398415 0.78 MEN1 (0.39) MEN1POLBKMT2AKDM4ETSHR
SCHEMBL7287117 0.77
SCHEMBL23979778 0.75 KMT2A (0.40) MEN1POLBKMT2AKDM4ETSHR
SCHEMBL8057836 0.74 ALDH1A1 (0.36) TSHRLMNAALDH1A1
SCHEMBL7755870 0.73 MEN1 (0.35) MEN1POLBKMT2AKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1155000-B1 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS PFIZER PROD INC (US) 2003-07-16 EP disclosed
US-6372768-B2 NERVOUS SYSTEM DISORDERS PFIZER INC 2002-04-16 US disclosed
EP-1155000-A1 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS Pfizer Products Inc. (US) 2001-11-21 EP disclosed
US-20010014689-A1 2-aminopyridines containing fused ring substituents LOWE JOHN A (US) 2001-08-16 US disclosed
US-6211208-B1 INHIBITION OF NITRIC OXIDE SYNTHETASE, ANTIINFLAMMATORY AGENTS PFIZER INC 2001-04-03 US disclosed
WO-2000050400-A1 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS PFIZER PRODUCTS INC. (US) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010014689-A1 2-aminopyridines containing fused ring substituents CBR1, CBR3, NOS2 MEN1 3960/4885POLB 3248/4885KMT2A 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.